#104169
#104170
Re: Farmas USA
TEVA
Me cago en... quien me mandaría vender ayer. En fin, así es la cosa.
14000 despidos (25% de la plantilla total) sin contar futuros cierres de plantas y oficinas, que también están previstos.
Aquí el resumen de la medidas, que se cargan también los dividendos:
-new unified and simplified organizational structure [...] by reducing layers of management, and simplifying business structures and processes
-optimization of the generics portfolio globally, and most specifically in the United States, through price adjustments and/or product discontinuation
- restructuring of its manufacturing and supply network, including the closures or divestments of a significant number of manufacturing plants in the United States, Europe, Israel and Growth Markets
-Closures or divestments of a significant number of R&D facilities, headquarters and other office locations across all geographies
- thorough review of all R&D programs across the entire company, in generics and specialty, to prioritize core projects and terminate others immediately, while maintaining a substantial pipeline
- suspend dividends on ordinary shares
The two year restructuring plan announced today is intended to reduce Teva's total cost base by $3 billion by the end of 2019, out of an estimated cost base for 2017 of $16.1 billion [...] restructuring charge as a result of the implementation of the plan in 2018 of at least $700 million
Edito: gustará al mercado, pero apostaría a que se va a cerrar el gap sin tardar muchos días
#104171
Re: Farmas USA
#104172
Re: Farmas USA
#104173
Re: Farmas USA
GILD CAR-T
-
Delays in getting novel therapy put sales estimates at risk
-
No Medicare coverage, one-by-one rulings by private insurers
#104174
Re: Farmas USA
CRISPR Therapeutics Plans First CRISPR/Cas9 Clinical Trial in Europe for 2018
#104175
Re: Farmas USA
se va muy afuera de las Bandas Bollinger ... me voy a pensar el corto ...
TEVA
#104176